CXCL1 and neoplasm: Although bioinformatics reveal that only 3.67% of BCs, from different stages of disease, included in the PanCancer collection, express CXCL1, the high incidence of this tumor, estimated at 2,000,000 cases per year worldwide, means that ∼73,000 patients are expected to be diagnosed with CXCL1+BC each year.